N-glycome analysis detects dysglycosylation missed by conventional methods in SLC39A8 deficiency
© 2020 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM..
Congenital disorders of glycosylation (CDG) are a growing group of inborn metabolic disorders with multiorgan presentation. SLC39A8-CDG is a severe subtype caused by biallelic mutations in the manganese transporter SLC39A8, reducing levels of this essential cofactor for many enzymes including glycosyltransferases. The current diagnostic standard for disorders of N-glycosylation is the analysis of serum transferrin. Exome and Sanger sequencing were performed in two patients with severe neurodevelopmental phenotypes suggestive of CDG. Transferrin glycosylation was analyzed by high-performance liquid chromatography (HPLC) and isoelectric focusing in addition to comprehensive N-glycome analysis using matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry (MS). Atomic absorption spectroscopy was used to quantify whole blood manganese levels. Both patients presented with a severe, multisystem disorder, and a complex neurological phenotype. Magnetic resonance imaging (MRI) revealed a Leigh-like syndrome with bilateral T2 hyperintensities of the basal ganglia. In patient 1, exome sequencing identified the previously undescribed homozygous variant c.608T>C [p.F203S] in SLC39A8. Patient 2 was found to be homozygous for c.112G>C [p.G38R]. Both individuals showed a reduction of whole blood manganese, though transferrin glycosylation was normal. N-glycome using MALDI-TOF MS identified an increase of the asialo-agalactosylated precursor N-glycan A2G1S1 and a decrease in bisected structures. In addition, analysis of heterozygous CDG-allele carriers identified similar but less severe glycosylation changes. Despite its reliance as a clinical gold standard, analysis of transferrin glycosylation cannot be categorically used to rule out SLC39A8-CDG. These results emphasize that SLC39A8-CDG presents as a spectrum of dysregulated glycosylation, and MS is an important tool for identifying deficiencies not detected by conventional methods.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Journal of inherited metabolic disease - 43(2020), 6 vom: 01. Nov., Seite 1370-1381 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Park, Julien H [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.10.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jimd.12306 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314261044 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314261044 | ||
| 003 | DE-627 | ||
| 005 | 20231225152341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jimd.12306 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314261044 | ||
| 035 | |a (NLM)32852845 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Park, Julien H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a N-glycome analysis detects dysglycosylation missed by conventional methods in SLC39A8 deficiency |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.10.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM. | ||
| 520 | |a Congenital disorders of glycosylation (CDG) are a growing group of inborn metabolic disorders with multiorgan presentation. SLC39A8-CDG is a severe subtype caused by biallelic mutations in the manganese transporter SLC39A8, reducing levels of this essential cofactor for many enzymes including glycosyltransferases. The current diagnostic standard for disorders of N-glycosylation is the analysis of serum transferrin. Exome and Sanger sequencing were performed in two patients with severe neurodevelopmental phenotypes suggestive of CDG. Transferrin glycosylation was analyzed by high-performance liquid chromatography (HPLC) and isoelectric focusing in addition to comprehensive N-glycome analysis using matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry (MS). Atomic absorption spectroscopy was used to quantify whole blood manganese levels. Both patients presented with a severe, multisystem disorder, and a complex neurological phenotype. Magnetic resonance imaging (MRI) revealed a Leigh-like syndrome with bilateral T2 hyperintensities of the basal ganglia. In patient 1, exome sequencing identified the previously undescribed homozygous variant c.608T>C [p.F203S] in SLC39A8. Patient 2 was found to be homozygous for c.112G>C [p.G38R]. Both individuals showed a reduction of whole blood manganese, though transferrin glycosylation was normal. N-glycome using MALDI-TOF MS identified an increase of the asialo-agalactosylated precursor N-glycan A2G1S1 and a decrease in bisected structures. In addition, analysis of heterozygous CDG-allele carriers identified similar but less severe glycosylation changes. Despite its reliance as a clinical gold standard, analysis of transferrin glycosylation cannot be categorically used to rule out SLC39A8-CDG. These results emphasize that SLC39A8-CDG presents as a spectrum of dysregulated glycosylation, and MS is an important tool for identifying deficiencies not detected by conventional methods | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a MALDI-TOF MS | |
| 650 | 4 | |a SLC39A8 | |
| 650 | 4 | |a congenital disorders of glycosylation | |
| 650 | 4 | |a glycosylation | |
| 650 | 4 | |a manganese | |
| 650 | 7 | |a Cation Transport Proteins |2 NLM | |
| 650 | 7 | |a SLC39A8 protein, human |2 NLM | |
| 650 | 7 | |a Transferrin |2 NLM | |
| 650 | 7 | |a Manganese |2 NLM | |
| 650 | 7 | |a 42Z2K6ZL8P |2 NLM | |
| 700 | 1 | |a Mealer, Robert G |e verfasserin |4 aut | |
| 700 | 1 | |a Elias, Abdallah F |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Grüneberg, Marianne |e verfasserin |4 aut | |
| 700 | 1 | |a Biskup, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Fobker, Manfred |e verfasserin |4 aut | |
| 700 | 1 | |a Haven, Jaclyn |e verfasserin |4 aut | |
| 700 | 1 | |a Mangels, Ute |e verfasserin |4 aut | |
| 700 | 1 | |a Reunert, Janine |e verfasserin |4 aut | |
| 700 | 1 | |a Rust, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Schoof, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Schwanke, Corbin |e verfasserin |4 aut | |
| 700 | 1 | |a Smoller, Jordan W |e verfasserin |4 aut | |
| 700 | 1 | |a Cummings, Richard D |e verfasserin |4 aut | |
| 700 | 1 | |a Marquardt, Thorsten |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of inherited metabolic disease |d 1978 |g 43(2020), 6 vom: 01. Nov., Seite 1370-1381 |w (DE-627)NLM000432628 |x 1573-2665 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2020 |g number:6 |g day:01 |g month:11 |g pages:1370-1381 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jimd.12306 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2020 |e 6 |b 01 |c 11 |h 1370-1381 | ||